CD17 (Huly-m13/H018.3G-6.F5) Antibody: sc-65253

lactosylceramide Background Information
CD17 (also designated Lactosylceramide or LacCer) is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsillar dendritic cells. It is rapidly downregulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor alpha (TNFå)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuroinflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.